PP-UR-GB-0451 January 2023

Please click here for Lyumjev®▼ (insulin lispro) PI: https://www.lillydiabetes.co.uk/assets/pdf/lyumjev_pi.pdf

Please click here for Humalog® (insulin lispro) PI: https://www.lillydiabetes.co.uk/assets/pdf/h2/ukie-humalog-digital-prescribing-information.pdf

Intended for Healthcare Professionals in Great Britain.

Lilly have sponsored the content of this meeting in partnership with ABCD. The speaker has been selected briefed and paid honorarium by Lilly. Lilly products will be discussed.

Lyumjev is indicated for people with diabetes mellitus in adults, adolescents and children aged 1 year and above. Lyumjev is not available in Ireland

Humalog® (insulin lispro) indicated for the treatment of adults and children with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis. Humalog is also indicated for the initial stabilisation of diabetes mellitus'

Meeting objectives:

- The challenge of post prandial hyperglcaemia
- The case for pump therapy vs MDI; Lyumjev®▼(insulin lispro) efficacy and safety in pumps
- Case Study Review

This presentation will include a 20 minute Q&A session

Lilly have sponsored the content of this meeting in partnership with ABCD. The speakers have been selected, briefed and paid honorarium by Lilly. Lilly products will be discussed at this meeting.

Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: http://www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store, or Ireland: www.hpra.ie. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000, or Lilly Ireland on 01 664 0446.

Lilly and Lyumjev® and Humalog® are registered trademarks of Eli Lilly and Company

© 2022 Eli Lilly and Company. All rights reserved

PP-UR-GB-0451 January 2023